PRESS RELEASE published on 03/20/2025 at 07:00, 1 year 4 months ago Informations privilégiées / Autres communiqués Innate Pharma organise une conférence téléphonique et un webcast pour présenter ses résultats financiers 2024. Détails de l'événement et informations pratiques disponibles sur www.innate-pharma.com Résultats Financiers Webcast Conférence Téléphonique Innate Pharma Biotechnologies
PRESS RELEASE published on 03/20/2025 at 07:00, 1 year 4 months ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 1 year 5 months ago Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
BRIEF published on 02/17/2025 at 07:07, 1 year 5 months ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 5 months ago Informations privilégiées / Autres communiqués Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA pour Lacutamab dans le syndrome de Sézary en rechute ou réfractaire. Accélération du développement réglementaire aux États-Unis FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 5 months ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 1 year 6 months ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
BRIEF published on 01/27/2025 at 07:05, 1 year 6 months ago Innate Pharma lance une étude de phase 1 sur IPH4502 dans les tumeurs solides avancées Innate Pharma Essai De Phase 1 IPH4502 Nectine-4 Tumeurs Solides Avancées
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 6 months ago Inside Information / Other news releases Innate Pharma announces first patient dosed in Phase 1 study of Nectin-4 targeting Antibody Drug IPH4502 in advanced solid tumors. Innovative ADC for multiple cancer types Innate Pharma Phase 1 Study IPH4502 Topoisomerase I Inhibitor Antibody Drug Conjugate
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 6 months ago Informations privilégiées / Autres communiqués Innate Pharma annonce le traitement du premier patient dans l'essai de phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées Innate Pharma Tumeurs Solides Conjugué Anticorps-médicament IPH4502 Nectine-4
Published on 08/11/2026 at 13:30, 29 minutes ago Nextech3D.ai CEO Evan Gappelberg Purchases 250,000 Shares in Open Market
Published on 08/11/2026 at 13:30, 29 minutes ago Algo Grande Provides Phase II Drill Update; Hole 2 Copper Zone Doubles as Hole 3 Delivers Extensive New Interval, Remains Mineralized at Depth
Published on 08/11/2026 at 13:00, 59 minutes ago AI/ML Innovations' Subsidiary NeuralCloud Achieves ISO 13485:2016 (MDSAP) Certification
Published on 08/11/2026 at 12:10, 1 hour 49 minutes ago CoTec Holdings Corp. Announces $20m Private Placement Of Unsecured Convertible Debentures
Published on 08/11/2026 at 12:00, 1 hour 59 minutes ago Bitterroot Resources Ltd. - Update on the LM Nickel-Copper Project, Michigan, USA
Published on 08/11/2026 at 13:40, 18 minutes ago Julius Meinl Living completes the sale of EUR 7.6 million of 2024 / 2029 notes
Published on 08/11/2026 at 13:05, 54 minutes ago Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
Published on 08/11/2026 at 12:40, 1 hour 19 minutes ago Green Street Launches Its MCP Server, Powered by GreenStreetAI™, Connecting CRE Intelligence Directly to Corporate Instances of Claude, ChatGPT, Gemini, and Other AI Platforms
Published on 08/11/2026 at 12:30, 1 hour 29 minutes ago Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Published on 08/10/2026 at 18:00, 19 hours 59 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 19 hours 59 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 20 hours 14 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 1 day 2 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
